These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

73 related articles for article (PubMed ID: 22398595)

  • 1. Companies in rapid pursuit of Btk immunokinase.
    Sheridan C
    Nat Biotechnol; 2012 Mar; 30(3):199-200. PubMed ID: 22398595
    [No Abstract]   [Full Text] [Related]  

  • 2. The biological rationale and clinical efficacy of inhibition of signaling kinases in chronic lymphocytic leukemia.
    de Weerdt I; Eldering E; van Oers MH; Kater AP
    Leuk Res; 2013 Jul; 37(7):838-47. PubMed ID: 23597579
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Bruton's tyrosine kinase inhibitors: lessons learned from bench-to-bedside (first) studies.
    Ysebaert L; Michallet AS
    Curr Opin Oncol; 2014 Sep; 26(5):463-8. PubMed ID: 25033375
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Bruton's tyrosine kinase as a drug discovery target.
    Pan Z
    Drug News Perspect; 2008 Sep; 21(7):357-62. PubMed ID: 19259548
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Breaking good: the inexorable rise of BTK inhibitors in the treatment of chronic lymphocytic leukaemia.
    Hutchinson CV; Dyer MJ
    Br J Haematol; 2014 Jul; 166(1):12-22. PubMed ID: 24749490
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Small-molecule inhibitors of spleen tyrosine kinase as therapeutic agents for immune disorders: will promise meet expectations?
    Lucas MC; Tan SL
    Future Med Chem; 2014; 6(16):1811-27. PubMed ID: 25407369
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Clinical potential of targeting Bruton's tyrosine kinase.
    Uckun FM
    Int Rev Immunol; 2008; 27(1-2):43-69. PubMed ID: 18300055
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Small molecules, big challenges.
    Cheson BD
    Oncology (Williston Park); 2015 Apr; 29(4):308-c3. PubMed ID: 25920930
    [No Abstract]   [Full Text] [Related]  

  • 9. Human Genome Sciences announces clearance of IND application for LymphoRad.
    Expert Rev Anticancer Ther; 2002 Jun; 2(3):246-7. PubMed ID: 12113047
    [No Abstract]   [Full Text] [Related]  

  • 10. Structural biology contributions to tyrosine kinase drug discovery.
    Cowan-Jacob SW; Möbitz H; Fabbro D
    Curr Opin Cell Biol; 2009 Apr; 21(2):280-7. PubMed ID: 19208462
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Antiarthritis effect of a novel Bruton's tyrosine kinase (BTK) inhibitor in rat collagen-induced arthritis and mechanism-based pharmacokinetic/pharmacodynamic modeling: relationships between inhibition of BTK phosphorylation and efficacy.
    Liu L; Di Paolo J; Barbosa J; Rong H; Reif K; Wong H
    J Pharmacol Exp Ther; 2011 Jul; 338(1):154-63. PubMed ID: 21521773
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Btk function in B cell development and response.
    Satterthwaite AB; Li Z; Witte ON
    Semin Immunol; 1998 Aug; 10(4):309-16. PubMed ID: 9695187
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Bruton's tyrosine kinase as a molecular target in treatment of leukemias and lymphomas as well as inflammatory disorders and autoimmunity.
    Uckun FM; Qazi S
    Expert Opin Ther Pat; 2010 Nov; 20(11):1457-70. PubMed ID: 20831363
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Imidazo[1,5-a]quinoxalines as irreversible BTK inhibitors for the treatment of rheumatoid arthritis.
    Kim KH; Maderna A; Schnute ME; Hegen M; Mohan S; Miyashiro J; Lin L; Li E; Keegan S; Lussier J; Wrocklage C; Nickerson-Nutter CL; Wittwer AJ; Soutter H; Caspers N; Han S; Kurumbail R; Dunussi-Joannopoulos K; Douhan J; Wissner A
    Bioorg Med Chem Lett; 2011 Nov; 21(21):6258-63. PubMed ID: 21958547
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Predicting Progression--ZAP-70 in CLL.
    Hamblin TJ
    N Engl J Med; 2004 Aug; 351(9):856-7. PubMed ID: 15329421
    [No Abstract]   [Full Text] [Related]  

  • 16. Drug discovery: New Btk inhibitor holds promise.
    Hendriks RW
    Nat Chem Biol; 2011 Jan; 7(1):4-5. PubMed ID: 21164510
    [No Abstract]   [Full Text] [Related]  

  • 17. The many faces of Bruton's tyrosine kinase.
    McAtee CP
    Nat Biotechnol; 2012 May; 30(5):394. PubMed ID: 22565960
    [No Abstract]   [Full Text] [Related]  

  • 18. The specific Bruton tyrosine kinase inhibitor acalabrutinib (ACP-196) shows favorable
    Golay J; Ubiali G; Introna M
    Haematologica; 2017 Oct; 102(10):e400-e403. PubMed ID: 28642301
    [No Abstract]   [Full Text] [Related]  

  • 19. Expression of Bruton's agammaglobulinemia tyrosine kinase gene, BTK, is selectively down-regulated in T lymphocytes and plasma cells.
    Smith CI; Baskin B; Humire-Greiff P; Zhou JN; Olsson PG; Maniar HS; Kjellén P; Lambris JD; Christensson B; Hammarström L
    J Immunol; 1994 Jan; 152(2):557-65. PubMed ID: 8283037
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Discovery of selective irreversible inhibitors for Bruton's tyrosine kinase.
    Pan Z; Scheerens H; Li SJ; Schultz BE; Sprengeler PA; Burrill LC; Mendonca RV; Sweeney MD; Scott KC; Grothaus PG; Jeffery DA; Spoerke JM; Honigberg LA; Young PR; Dalrymple SA; Palmer JT
    ChemMedChem; 2007 Jan; 2(1):58-61. PubMed ID: 17154430
    [No Abstract]   [Full Text] [Related]  

    [Next]    [New Search]
    of 4.